AgingResearch.NewsJoin free

Kyowa Kirin

CompanyJapan

Kyowa Kirin develops one asset, in phase 2 (KHK4951 in diabetic macular edema). Mostly small molecule acting on FLT1, FLT4 and KDR; based in Japan.

1
Asset
Furthest stage
Phase 2
9
Trials
1
Signal

Pipeline

1

  • KHK4951

    Inhibits vascular endothelial growth factor receptors to reduce retinal vascular leakage and edema.

    Phase 2, Small molecule, FLT1, FLT4, diabetic macular edema, neovascular age-related macular degeneration

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials14
  • Signals3
  • Similar companies6

Papers

Intelligence